{"filings":[{"id":1471436,"accession_number":"0001193125-26-296174","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2026-07-06T20:06:28+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Achieve Life Sciences shareholders approve doubling authorized common shares to 300M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved Certificate of Amendment increasing authorized common shares from 150M to 300M.","All nine director nominees elected, including Jeffrey Farrow, Andrew Goldberg, and others.","Ratification of PricewaterhouseCoopers LLP as independent auditor for FY 2026 approved.","Non-binding advisory vote on named executive officer compensation passed with 46.4M for, 0.6M against.","Certificate of Amendment filed with Delaware Secretary of State on July 6, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":788316,"accession_number":"0001193125-26-252624","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2026-06-02T12:51:39+00:00","items":["5.02"],"status":"ready","headline":"Achieve Life Sciences appoints Jeff Farrow and Dr. Reid Waldman to Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeff Farrow appointed to Audit Committee as Chair and Nominating & Governance Committee as member.","Dr. Reid Waldman appointed to Compensation Committee as Chair and Commercial Committee as member.","Each new director receives pro-rated $40,000 annual retainer for FY 2026 plus committee cash compensation.","Each receives a stock option for 47,250 shares vesting monthly over three years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22401,"accession_number":"0001193125-26-218175","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2026-05-12T11:20:21+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Q1 cash $29.3M; closed $180M upfront financing; expects CRL by June 20, 2026; new CEO appointed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 cash, equivalents, and marketable securities $29.3M; net loss $10.2M, operating expenses $10.5M.","Closed private placement of up to $354M ($180M upfront + $174M milestone warrants).","Andrew D. Goldberg, MD appointed CEO and board member; Christopher Martin added as director.","Expects CRL from FDA by June 20, 2026; to resubmit NDA in Q4 2026 with new manufacturer Adare.","Jaime Xinos departs as CCO May 31; Lucian Iancovici becomes Chair; Tom King steps down June 8."],"consensus_eps_estimate":-0.3145,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99977,"accession_number":"0001193125-26-159189","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["1.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Achieve Life Sciences raises $180M in private placement (up to $354M with warrants); CEO replaced","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $180M upfront; warrants could add $174M if FDA approves cytisinicline for smoking cessation.","CEO Richard Stewart steps down April 18; remains on board. New CEO Andrew Goldberg appointed.","Board adds directors Lucian Iancovici and Aaron Royston; Frazier Life Sciences to designate a third.","Proceeds to fund Phase 3 e-cigarette cessation trial and commercialization of cytisinicline.","Warrants exercise price $3.51, expire 20 business days after FDA approval announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116291,"accession_number":"0001193125-26-120687","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Achieve Life Sciences reports Q4/FY2025 net loss $54.7M; cytisinicline NDA PDUFA June 20, 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $36.4M at Dec 31, 2025; net loss $14.7M Q4 and $54.7M FY2025.","FDA accepted cytisinicline NDA for smoking cessation; PDUFA action date June 20, 2026.","Partnered with Adare Pharma Solutions for US-based manufacturing; tech transfer begun.","Anticipates US commercial launch in first half 2027.","Completed ORCA-OL one-year safety study with 334 participants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132757,"accession_number":"0001193125-25-268056","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ACHV Q3 net loss $14.4M; FDA accepts cytisinicline NDA, PDUFA June 20, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Net loss $14.4M for Q3 2025; cash, equivalents & marketable securities $48.1M at Sep 30.","FDA accepted cytisinicline NDA for smoking cessation; PDUFA target action date June 20, 2026.","FDA awarded Commissioner’s National Priority Voucher for vaping cessation, enabling 1-2 month expedited review.","Appointed Erik Atkisson as Chief Legal Officer; over 25 years biopharma legal experience.","New post hoc data in Thorax shows cytisinicline improved quit rates in adults with COPD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132756,"accession_number":"0001193125-25-233581","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Achieve Life Sciences CMO/President Dr. Cindy Jacobs resigns; stays as consultant through NDA approval","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Jacobs resigned as Chief Medical Officer and President effective Oct 6, 2025.","Separation agreement includes lump-sum cash severance of $101,296 (prorated 2025 bonus).","She will serve as consultant until first business day after FDA NDA approval for cytisinicline.","Unvested time-based options from Jan 2023/Jan 2024 to accelerate upon consultancy end; exercise period extended to 12 months.","Company will reimburse up to $10,000 in legal fees for negotiation of separation and consulting agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149290,"accession_number":"0001193125-25-201418","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Achieve Life Sciences CMO/President Cindy Jacobs resigns effective Oct 6, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Cindy Jacobs resigned as Chief Medical Officer and President, effective October 6, 2025.","Company is negotiating a consulting agreement for Dr. Jacobs to continue advisory services after resignation.","No successor named; board to oversee transition and search."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149289,"accession_number":"0000950170-25-104569","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Achieve Life Sciences submits cytisinicline NDA to FDA; cash position $55.4M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NDA submitted to FDA in June 2025 for cytisinicline as smoking cessation treatment in adults.","Raised $49.3M gross from underwritten public offering in June-July 2025; expects runway into H2 2026.","Partnered with Omnicom for integrated launch strategy, reducing internal commercial buildout costs.","ORCA-OL safety requirements met: >300 subjects with ≥6 months, >100 with ≥1 year cumulative exposure.","Q2 2025 net loss $12.7M; operating expenses $12.6M; cash & securities $55.4M as of June 30."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168319,"accession_number":"0000950170-25-091055","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Achieve Life Sciences prices $45M offering: 15M shares and warrants at $3.00 per unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Public offering of 15M shares of common stock and accompanying warrants to purchase up to 15M shares, priced at $3.00 per unit.","Gross proceeds ~$45M; net proceeds ~$41.3M after underwriting discounts and expenses; expected close June 30, 2025.","Underwriters granted 30-day option to purchase up to an additional 2.25M shares and/or warrants.","Each warrant exercisable for one share at $3.00, or exchangeable for pre-funded warrant at $0.001/share; 5-year term; 9.99% ownership cap.","Proceeds to fund cytisinicline advancement for smoking cessation through potential FDA approval and for working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168318,"accession_number":"0000950170-25-083214","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Achieve Life Sciences shareholders reject director equity plan increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected with majority 'for' votes; broker non-votes 11,422,484.","Ratification of PwC as auditor for FY2025 approved: 26,459,791 for, 53,879 against.","Amendment to 2023 Non-Employee Director Equity Incentive Plan to increase shares failed: 6,736,105 for, 7,982,633 against.","Proposal required majority of votes cast; failure may impact director compensation strategy.","Broker non-votes (11,422,484) were not counted on non-routine matters, effectively against the plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168317,"accession_number":"0000950170-25-069804","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q1 net loss $12.8M; on track for cytisinicline NDA submission to FDA in June 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and marketable securities totaled $23.2M; operating expenses $12.9M for Q1 2025.","Plans to submit NDA for cytisinicline to FDA in June 2025; ORCA-3 results published in JAMA Internal Medicine.","ORCA-OL long-term safety trial met FDA requirements: >300 patients with 6 months, >100 with 1 year treatment.","DSMC third safety review found no concerns; SAB meeting held in May 2025 with ten nicotine cessation experts."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185498,"accession_number":"0000950170-25-036830","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Achieve Life Sciences reports Q4 net loss $12.4M; reiterates cytisinicline NDA by end of Q2 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and marketable securities $34.4M as of Dec 31, 2024.","Net loss for Q4 2024 was $12.4M; full-year net loss $39.8M (pre-revenue).","NDA submission for smoking cessation cytisinicline expected end of Q2 2025; ORCA-OL enrollment complete.","Appointed Mark Oki as CFO, Dr. Kristen Slaoui and Nancy Phelan to Board.","FDA agreed Phase 3 ORCA-V2 trial design for vaping cessation; plans to initiate in H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185497,"accession_number":"0000950170-25-017068","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Achieve DSMC finds no safety concerns in ORCA-OL; NDA on track for Q2 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DSMC completed second independent review of ORCA-OL trial; no unexpected treatment-related adverse events identified.","Participants' adherence to cytisinicline was excellent; study continues as planned without modifications.","Achieve reiterates planned New Drug Application submission for cytisinicline in Q2 2025.","ORCA-OL enrolled 479 participants across 29 US sites; 300+ completed six months of cumulative cytisinicline treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185496,"accession_number":"0000950170-25-003873","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Achieve Life Sciences appoints Nancy Phelan and Kristen Slaoui to board; Himes resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Vaughn Himes resigned from board effective Jan 6, 2025; no disagreement; will continue consulting.","Board appointed Nancy R. Phelan and Kristen B. Slaoui, Ph.D. as directors, effective Jan 6, 2025.","Each new director receives $40,000 annual retainer for FY2025 and stock option for 47,250 shares (3-yr vest).","Additionally, annual equity option for 31,500 shares vesting over one year, subject to continued service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202089,"accession_number":"0000950170-24-134558","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Achieve Life Sciences appoints Mark K. Oki as CFO effective December 5, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Oki previously CFO of Aytu Biopharma, Vivus LLC, Alexza Pharmaceuticals.","Base salary $450,000/year; annual discretionary bonus up to 40% of base.","Awarded option for 72,000 shares (1/3 vest year 1, then monthly) and 168,000 performance-based RSUs.","Severance: 12 months salary (24 months on change in control) plus healthcare and accelerated equity vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202088,"accession_number":"0000950170-24-123334","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Achieve Life Sciences Q3 net loss $12.5M; ORCA-OL enrollment complete, NDA on track for Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and investments $42.9M as of Sep 30, 2024; operating expenses $12.5M for Q3.","Completed enrollment in Phase 3 ORCA-OL trial with 479 participants across 29 U.S. sites.","FDA granted Breakthrough Therapy designation for cytisinicline for nicotine e-cigarette (vaping) cessation.","Leadership: Richard Stewart named CEO, Thomas King Executive Chairman, Jaime Xinos Chief Commercial Officer.","Planned NDA submission in Q2 2025; Data Safety Monitoring Committee found no safety concerns."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218127,"accession_number":"0000950170-24-110066","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Achieve Life Sciences enters $50M ATM equity offering with Jefferies for cytisinicline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Open Market Sale Agreement with Jefferies for at-the-market offering of up to $50M of common stock.","Jefferies receives up to 3% commission; company has no obligation to sell and may suspend at any time.","Proceeds to fund clinical development of cytisinicline for smoking cessation and general corporate purposes.","Offering made under existing S-3 registration statement filed June 28, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218126,"accession_number":"0001193125-24-207129","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2024-08-26T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"CEO John Bencich departs; Richard Stewart named CEO, Thomas King Executive Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Bencich removed as CEO effective Aug 21, 2024; receives lump-sum severance of 18-month base salary and accelerated equity vesting.","Richard Stewart, previously Executive Chairman, appointed CEO effective Aug 21; base salary $615K, annual bonus up to 50%, 157,500 performance RSUs and 67,500 stock options.","Thomas King appointed Executive Chairman; base salary $495K, option for 195,000 shares, 455,000 performance RSUs.","King steps down from Compensation, Audit, and Nominating committees; Thomas Sellig appointed Compensation Committee Chair."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218125,"accession_number":"0000950170-24-096171","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Achieve Life Sciences Q2 net loss $8.5M; FDA Breakthrough Therapy for cytisinicline vaping cessation","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $8.5M vs $8.0M prior year; cash & equivalents $61.3M as of June 30, 2024.","FDA granted Breakthrough Therapy designation for cytisinicline for nicotine e-cigarette cessation; no FDA-approved treatments exist.","Refinanced up to $20M loan with SVB; maturity extended to Dec 1, 2027 from Aug 1, 2024.","Initiated ORCA-OL trial for long-term cytisinicline exposure; over 50% of 650 participants enrolled.","Included in Russell 3000 and Russell Microcap indexes effective July 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218124,"accession_number":"0000950170-24-087118","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["2.03","1.01","3.02","9.01"],"status":"ready","headline":"Achieve Life Sciences enters $10M convertible debt agreement with Silicon Valley Bank, up to $20M total","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial $10M term loan funded July 25, 2024; up to $10M additional subject to FDA NDA acceptance and lender approval.","Interest at greater of 7.0% or prime minus 1.0%; interest-only until Dec 31, 2025; maturity Dec 1, 2027 (extendable to Jun 1, 2028).","Conversion rights: initial conversion price $7.00/share, up to 1.43M shares; subsequent tranches at higher of $4.854 or 150% of trailing 10-day VWAP.","Refinanced prior 2023 convertible debt of $16.6M; obligations satisfied and terminated.","Registration rights granted to lender for resale of conversion shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238088,"accession_number":"0000950170-24-078445","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Achieve Life Sciences enters non-binding term sheet to refinance up to $20M SVB loans, extend maturity to June 2028","summary_kind":"llm","event_type":"debt","confidence":"medium","bullets":["Non-binding term sheet for up to $20M tranched facility from Silicon Valley Bank.","New loans mature June 1, 2028; interest-only payments through Dec 31, 2025.","Parties anticipate closing before current loan maturity of August 1, 2024.","No assurance that definitive agreement will be reached on these terms or at all."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238087,"accession_number":"0000950170-24-069973","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Achieve Life Sciences shareholders elect 8 directors, ratify PwC as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 8 director nominees elected with 14.1M–14.6M votes 'For'; broker non-votes of 10.2M.","Ratification of PwC as independent auditor for FY 2024: 24.8M For, 230.6K Against, 218.3K Abstain.","Meeting held June 5, 2024; results reported June 6, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238086,"accession_number":"0000950170-24-056876","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Achieve Life Sciences reports Q1 net loss of $6.5M; cash $66.4M; ORCA-OL trial starts May 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, restricted cash $66.4M as of March 31, 2024, after $60M upfront financing.","Net loss for Q1 2024 was $6.5M; total operating expenses $6.0M.","Feb 2024 financing raised $60M upfront with potential $64.2M from milestone-driven warrants.","ORCA-OL long-term safety trial on track to initiate enrollment in May 2024; NDA submission expected H1 2025.","Phase 2 ORCA-V1 vaping cessation results published in JAMA Internal Medicine."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255555,"accession_number":"0000950170-24-038030","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Achieve Life Sciences reports 2023 net loss of $29.8M; FDA agrees on NDA path for cytisinicline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2023: $5.5M; full-year 2023 net loss: $29.8M; operating expenses $27.3M.","Cash $15.6M at Dec 31, 2023; pro forma $71.8M after Feb 2024 equity financing of up to $124.2M.","FDA agreed single open-label safety study (ORCA-OL) is sufficient; NDA submission expected H1 2025.","Phase 3 ORCA-2/3 and Phase 2 ORCA-V1 data at SRNT: 69% of cytisinicline users quit smoking; 97% would recommend.","Shares outstanding as of March 28, 2024: 34,251,911."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255554,"accession_number":"0000950170-24-023189","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["1.01","1.02","2.02","3.02","7.01","9.01"],"status":"ready","headline":"Achieve Life Sciences raises up to $124.2M in registered direct offering and private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$60M upfront from 13.09M shares at $4.585; warrants could add $64.2M at $4.906 exercise price.","Preliminary cash, cash equivalents and restricted cash of $15.6M as of Dec 31, 2023.","Net proceeds to fund cytisinicline clinical development through NDA submission expected 1H 2025.","Warrants exercisable for 3.5 years or expire 30 days after FDA Day 74 letter acceptance; 4.99% ownership cap.","Concurrent termination of at-the-market sales agreement with Virtu Americas LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273010,"accession_number":"0000950170-23-069392","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Achieve Life Sciences: FDA requires long-term safety data; NDA filing likely delayed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA supports NDA on two Phase 3 trials but demands long-term safety data beyond 12 weeks for chronic-use label.","Company expects further FDA input in Q1 2024; NDA submission timing may be delayed.","Long-term safety data may be collected from cumulative treatment and vaping cessation program.","Single drug candidate cytisinicline at risk; delay could impact regulatory timeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273009,"accession_number":"0000950170-23-062005","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Achieve Life Sciences reports Q3 2023 net loss $7.1M; cash $20M; advances cytisinicline trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and restricted cash $20.0M as of Sep 30, 2023; net loss $7.1M in Q3 2023.","ORCA-2 Phase 3 smoking cessation results published in JAMA; cytisinicline showed significant efficacy.","Completed dosing of three NDA-supportive studies (QT, PK in smokers, renal impairment); data due early 2024.","Phase 2 ORCA-V1 results presented: 2.6-fold increase in vaping cessation odds vs placebo.","Shares outstanding: 21,165,760 as of Nov 9, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289849,"accession_number":"0000950170-23-042382","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Achieve Life Sciences Q2 net loss $8.2M, cash $25.1M; advances cytisinicline NDA submission H1 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $8.2M in Q2 2023; cash, equivalents and restricted cash $25.1M as of June 30, 2023.","Positive Phase 3 ORCA-3 trial confirmed cytisinicline efficacy/safety for smoking cessation in 792 smokers.","Phase 2 ORCA-V1: cytisinicline increased odds of quitting vaping 2.6x vs placebo (31.8% vs 15.1%).","Plan to submit New Drug Application for cytisinicline in first half of 2024.","Raised $16.5M in registered direct offering; refinanced $16.6M SVB debt with maturity to Dec 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310783,"accession_number":"0001193125-23-164423","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Achieve Life Sciences holds annual meeting; approves officer exculpation charter amendment and 2023 equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Eight directors elected at June 7 annual meeting: Bencich, Duty, Himes, Jacobs, King, Martell, Sellig, Stewart.","Stockholders approved amendment to certificate of incorporation to permit officer exculpation under DGCL (9.2M for, 162k against).","Auditors PricewaterhouseCoopers LLP ratified for FY2023 (13.9M for, 93k against).","Non-binding advisory vote on executive compensation passed; future say-on-pay votes every three years.","2023 Non-Employee Director Equity Incentive Plan approved (8.4M for, 898k against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310782,"accession_number":"0000950170-23-024074","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2023-05-25T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Achieve Life Sciences prices $16.5M registered direct offering of 3M shares at $5.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 3,000,000 shares at $5.50 each for gross proceeds of ~$16.5M; net proceeds ~$15.2M.","Offering includes participation from current investors Dialectic Life Sciences, Hunt Family affiliates, and management.","Proceeds to fund cytisinicline development for smoking cessation and for working capital.","Expected to close on or about May 30, 2023; Lake Street Capital Markets as placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310781,"accession_number":"0000950170-23-023533","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2023-05-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Achieve Life Sciences reports positive Phase 3 ORCA-3 data; 12-week cytisinicline 30.3% quit rate vs 9.4% placebo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["12-week cytisinicline: 30.3% quit rate last 4 wks, 4.4x odds vs placebo (p<0.0001); continuous abstinence wk9-24: 20.5% vs 4.2%","6-week cytisinicline: 14.8% quit rate last 4 wks, 2.85x odds vs placebo (p=0.0008); continuous abstinence wk3-24: 6.8% vs 1.1%","No treatment-related serious adverse events; common side effects: insomnia (11.9% 12-wk), abnormal dreams, nausea, headache","ORCA-3 enrolled 792 adult smokers at 20 US sites; results consistent with prior Phase 3 ORCA-2 study","Cytisinicline could be first new prescription smoking cessation treatment in ~20 years; conference call May 23 at 8:30AM EDT"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310780,"accession_number":"0000950170-23-022609","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2023-05-17T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Achieve Life Sciences enters $16.56M contingent convertible loan facility, refinancing prior debt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Term loan of $16.56M from Silicon Valley Bank/FCB and affiliates to refinance existing $15M contingent convertible debt.","Conversion price set at $9.34/share; mandatory conversion if stock closes at ≥$24 for 30 consecutive trading days.","Maturity Dec 22, 2024, accelerated to Aug 1, 2024 if NDA filing not accepted by July 31, 2024.","Issuer may call loan at 125% of principal before June 22, 2023, or 150% after; Lenders waived call price on prior loan.","Loan secured by substantially all assets except intellectual property; Lenders restricted from short sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310779,"accession_number":"0000950170-23-019679","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q1 net loss $9.0M; cash $16.6M; Phase 2 vaping cessation data positive; Phase 3 ORCA-3 topline due Q2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.0M for Q1 2023; cash, equivalents & restricted cash $16.6M as of March 31, 2023.","Phase 2 ORCA-V1 trial: cytisinicline 31.8% quit rate vs placebo 15.1%; 2.6x odds (p=0.035).","Phase 3 ORCA-3 trial (792 adults) fully enrolled; topline results expected Q2 2023.","Three new board members appointed: Stuart Duty, Thomas King, and Tom Sellig.","Shares outstanding: 18,040,760 as of May 9, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310778,"accession_number":"0000950170-23-017164","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Achieve Life Sciences updates principal executive offices to two locations effective April 28, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective April 28, 2023, Achieve Life Sciences established principal executive offices at 1040 West Georgia, Suite 1030, Vancouver, BC, Canada V6E 4H1.","Also effective April 28, 2023, the Company's principal executive offices include 22722 29th Drive SE, Suite 100, Bothell, WA 98021.","The address change was disclosed under Item 7.01 Regulation FD Disclosure in an 8-K filed May 3, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329403,"accession_number":"0001564590-23-004687","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Achieve Life Sciences appoints three new directors; three incumbents not standing for reelection","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stuart Duty, Thomas King, and Tom Sellig appointed to board effective March 29, 2023.","Donald Joseph, Martin Mattingly, and Jay Moyes will not stand for reelection at June 2023 annual meeting.","Appointments made under Cooperation Agreement with Dialectic Capital Management dated March 1, 2023.","New directors each receive pro-rata $40K annual retainer and initial option for 24,000 shares vesting over 3 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329402,"accession_number":"0001564590-23-004277","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2023-03-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Achieve Life Sciences to appoint three new board directors by April 3 under amended pact with Dialectic","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to March 1 Cooperation Agreement requires three new Board appointments by April 3, 2023.","Board may expand to up to 11 directors to fill vacancies via incumbent departures or size increase.","New directors will be nominated for election at the 2023 Annual Meeting.","Dialectic Capital Management and affiliates, including John Fichthorn, are parties to the amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329401,"accession_number":"0001564590-23-003792","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2023-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Achieve Life Sciences reports Q4/FY 2022 net loss $42.4M; cash $24.8M; phase 3/2 trial data due Q2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, and restricted cash totaled $24.8M as of Dec 31, 2022.","Net loss for FY 2022 was $42.4M; Q4 2022 net loss $11.2M.","Phase 3 ORCA-3 and Phase 2 ORCA-V1 top-line results expected in Q2 2023.","Closed $18.9M private placement in Nov 2022 to fund trials and working capital.","USPTO granted patent for cytisinicline mesylate salt formulation, expiring 2042."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329400,"accession_number":"0001564590-23-003159","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2023-03-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Achieve Life Sciences enters cooperation agreement with Dialectic Capital; appoints three new directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company to appoint three Designees to Board by March 21, 2023, filling vacancies from incumbent departures or board expansion.","Board size to be set at eight directors by 2023 Annual Meeting; incumbent directors may resign to comply.","Dialectic agrees to standstill, voting commitments, and non-disparagement until Expiration Date (generally 15 business days before 2024 annual meeting).","Designees to be nominated for election at 2023 Annual Meeting; at least one Designee on each committee except CMC.","Agreement terminates if Dialectic ownership falls below 10% or material breach."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347004,"accession_number":"0001564590-22-038292","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2022-11-25T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Achieve Life Sciences receives Nasdaq delisting notice for low equity; plans to submit compliance plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders' equity as of Sept 30, 2022 was $1.0M, below Nasdaq's $2.5M minimum.","Nasdaq gave 45 days (until Jan 6, 2023) to submit a plan to regain compliance.","Company expects to submit plan citing recent private offering to boost equity.","If plan accepted, Nasdaq may grant up to 180 days extension; if not, delisting possible.","No immediate effect on trading; stock continues on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347003,"accession_number":"0001564590-22-038025","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2022-11-18T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Achieve Life Sciences raises $18.9M in private placement of units at $4.625/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$18.9M from sale of 4,093,141 units at $4.625/unit; each unit consists of 2 common shares and a warrant to buy one share.","Pricing represents an 8.6% premium to prior day's closing price ($2.3125 per common share).","Net proceeds ~$17.9M after expenses; funds operations into late 2023; used for clinical R&D and working capital.","Warrants exercisable at $4.50/share for 7 years, beginning 6 months after close; callable under certain conditions.","Placement includes new life sciences fund, management participation, and existing investors; Lake Street Capital Markets as exclusive placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347002,"accession_number":"0001564590-22-037625","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Achieve Life Sciences Q3 net loss $13.1M; Phase 3 ORCA-3 and Phase 2 ORCA-V1 enrollment completed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.1M for Q3 2022; operating expenses $12.6M; cash and restricted cash $18.2M as of Sept 30, 2022.","Phase 3 ORCA-3 trial of cytisinicline enrolled 750 adult smokers; topline data expected Q2 2023.","Phase 2 ORCA-V1 trial of cytisinicline in 150 e-cigarette users completed enrollment early; topline data expected Q2 2023.","Sopharma completed new API purification suite for cytisinicline with >€3M cost, expanding global production capacity.","9,710,747 shares outstanding as of Nov 10, 2022; no revenue (pre-commercial stage)."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363386,"accession_number":"0001564590-22-029119","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Achieve Life Sciences Q2 net loss $10.5M; Phase 3 success and $2.5M NIH grant","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2022 net loss of $10.5M; operating expenses $10.1M; cash & restricted cash $29.4M as of June 30.","Phase 3 ORCA-2 trial in 810 smokers: 6–8x increased odds of smoking abstinence vs placebo (statistically significant).","Awarded $2.5M NIH grant for Phase 2 ORCA-V1 trial evaluating cytisinicline in e-cigarette users; trial initiated.","ORCA-3, the final NDA-enabling smoking cessation trial, continues enrolment."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383191,"accession_number":"0001564590-22-022030","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2022-06-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Achieve Life Sciences stockholders re-elect eight directors and ratify auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected; votes ranged from 2,084,415 (Richard Stewart) to 2,226,016 (John Bencich) in favor.","Ratification of PricewaterhouseCoopers as independent auditor for FY2022: 6,661,313 for, 18,435 against, 2,517 abstain.","Broker non-votes of 4,403,156 on director elections due to discretionary voting rules.","Meeting held May 31, 2022; no other matters submitted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383190,"accession_number":"0001564590-22-019857","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Achieve reports Q1 net loss $7.6M; positive Phase 3 ORCA-2 cytisinicline results","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.6M for Q1 2022; cash & equivalents $36.4M as of March 31, 2022.","Phase 3 ORCA-2 cytisinicline met primary endpoints: 12-week abstinence 32.6% vs 7.0% placebo.","Updated SVB debt facility provides remaining $10M available through April 2023.","Appointed Dr. Vaughn Himes (CTO of Seagen) to Board of Directors in March 2022.","Operating expenses $7.2M for Q1; shares outstanding 9,681,855 as of May 12, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383189,"accession_number":"0001564590-22-015873","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2022-04-27T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Achieve Life Sciences reports positive Phase 3 ORCA-2 results; cytisinicline shows 6-8x odds of smoking abstinence","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoints met: 12-week cytisinicline had 32.6% abstinence vs 7.0% placebo (OR 6.3, p<0.0001); 6-week had 25.3% vs 4.4% (OR 8.0, p<0.0001).","Secondary continuous abstinence weeks 9-24: 21.1% for 12-week arm vs 4.8% placebo (OR 5.3, p<0.0001); weeks 3-24: 8.9% vs 2.6% (OR 3.7, p=0.0016).","Well tolerated; no treatment-related serious adverse events. Most common AEs (>5%): insomnia, abnormal dreams, headache, nausea.","SVB approved remaining $10M of $25M debt facility; terms: interest at greater of 3.5% or WSJ prime, interest-only through Apr 2024, then 24-month amortization.","Facility available through Apr 30, 2023; no amounts drawn at close; discretionary draws allowed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400989,"accession_number":"0001564590-22-010148","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2022-03-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Achieve Life Sciences appoints Vaughn Himes, PhD to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Himes appointed as director effective March 14, 2022; no committee assignment yet.","Annual cash retainer of $40,000 for Board service.","Initial option grant for 6,600 shares, vesting monthly over 36 months, exercise price at Nasdaq close on grant date.","No arrangements, family relationships, or material interests per Item 404(a) reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400988,"accession_number":"0001564590-22-009483","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2022-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Achieve Life Sciences reports FY2021 net loss $33.2M; Phase 3 ORCA-2 topline data expected Q2 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and restricted cash of $43.1M as of Dec 31, 2021.","Total operating expenses for FY2021 were $33.1M; net loss $33.2M.","Initiated Phase 3 ORCA-3 trial; ORCA-2 completed with topline results due Q2 2022.","Entered $25M loan facility with Silicon Valley Bank in December 2021.","FDA accepted IND for cytisinicline in e-cigarette/vaping cessation; Phase 2 ORCA-V1 expected Q2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419931,"accession_number":"0001564590-21-060919","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2021-12-22T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Achieve Life Sciences enters $15M contingent convertible debt agreement with SVB","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$15M initial term loan from SVB and SVB Innovation Credit Fund VIII; up to $10M additional subject to approval.","Convertible at $9.34/share; mandatory conversion if stock closes at $24+ for 30 consecutive trading days.","Interest: floating (prime−1%, floor 2.25%) cash + 7% PIK compounded monthly.","Maturity Dec 22, 2023, extendable to Dec 22, 2024 upon mutual agreement; prepayment penalties apply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419930,"accession_number":"0001564590-21-055716","cik":949858,"company_name":"ACHIEVE LIFE SCIENCES, INC.","ticker":"ACHV","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Achieve Life Sciences Q3 net loss $6.7M; ORCA-2 topline data expected H1 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash equivalents $33.4M; total operating expenses $6.7M for Q3, $26.0M for 9 months.","ORCA-2 Phase 3 completed treatment; topline data expected first half 2022.","ORCA-3 Phase 3 enrollment of ~750 subjects to start by early 2022.","FDA accepted IND for cytisinicline e-cigarette cessation trial; ORCA-V1 to start Q2 2022.","Two U.S. patents issued for 3.0 mg TID dosing regimen, expiring 2040."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":518315338.8078032,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-11-09T23:59:59+00:00|419930"}